[Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer].
Imipenem/cilastatin sodium (IPM/CS) was administered to 102 patients with respiratory tract infections and lung cancer. Patients with other serious diseases were excluded and a total of 73 patients were enrolled. They were divided into 12 patients who underwent surgery (operated group) and 61 who did not (non-operated group); the latter group included 28 patients treated with anticancer agents or radiation therapy (treated group) and 33 untreated patients (untreated group). IPM/CS was effective in 75% of the patients, both with and without surgery. The drug was effective in 81% of the treated group, although many of the patients had Stage III or more advanced cancer, as well as bronchial occlusion. IPM/CS was also effective in 69% of the untreated group, although many of the patients have serious infections and a PS (Performance Status) of 3 or greater. Thus, IPM/CS treatment achieved good results. Bacteriological studies showed that 3 out of 4 strains in the operated group and 16 out of 18 in the non-operated group were eliminated. Safety was evaluated in all patients. Two patients (2%) experienced side effects and two others (2%) showed abnormal clinical findings, but the symptoms were mild and resolved after discontinuation or completion of therapy. In conclusion, IPM/CS was very effective for treating respiratory infections in patients with lung cancer.
Yoshida
M
M
Second Department of Internal Medicine, Fukuoka University.
Watanabe
K
K
Tanaka
H
H
Senju
S
S
Ishibashi
T
T
Takamoto
M
M
Oizumi
K
K
Kondo
Y
Y
Shigematsu
H
H
Ohno
T
T
Ichikawa
Y
Y
Hara
N
N
Mitsuyama
T
T
Nakanishi
Y
Y
Yamada
H
H
Kuroki
S
S
Motohiro
A
A
Ueda
H
H
Kusano
T
T
Hiratsuka
M
M
Nikaido
Y
Y
Kido
M
M
Miyahara
T
T
Ninomiya
K
K
Naoe
H
H
D000230:Adenocarcinoma / Q000150:complications / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018287:Carcinoma, Large Cell / Q000150:complications / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000150:complications / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000473:pathology; D015377:Cilastatin / Q000008:administration & dosage; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000150:complications* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy*
D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination